OncoMatch/Clinical Trials/NCT06300463
Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases
Is NCT06300463 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Botensilimab and Balstilimab for colorectal cancer metastatic.
Treatment: Botensilimab · Balstilimab · AGEN1423 — The goal of this clinical trial is to to learn about different combinations of immunotherapy in patients with colorectal cancer whose cancer has spread to their liver and are planning to have surgery to remove tumor metastases from their liver. The main questions it aims to answer are: * whether these combinations of immunotherapy change the tumor microenvironment in the liver * whether these combinations of immunotherapy are safe and effective when used in colorectal cancer with liver metastases Participants will be randomly assigned to one of the following: * Botensilimab and balstilimab * Botensilimab, balstilimab, and AGEN1423 * Botensilimab, balstilimab, and radiation Participants will be asked to come in to receive drug infusions (and radiation, if applicable) before and after their surgical resection. Participants will be followed for up to 2 years.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Disease stage
Metastatic disease required
Prior therapy
Cannot have received: anti-PD-1/PD-L1/CTLA-4 therapy
Previously received PD-1, PD-L1, or CTLA-4 therapy including experimental immunologic agents
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Weill Cornell Medicine/NewYork-Presbyterian Hospital · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify